Mechanism underlying severe de ficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura

被引:3
|
作者
Zheng, X. Long [1 ,2 ]
机构
[1] Univ Kansas Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd, Mail Stop Delp 5016, Kansas City, KS 66160 USA
[2] Univ Kansas Med Ctr, Inst Reprod Med & Dev Sci, Kansas City, KS USA
关键词
ADAMTS-13; autoantibodies; capillary Western blotting; TTP/HUS; von Willebrand factor; SPACER DOMAIN; ANTI-ADAMTS13; AUTOANTIBODIES; ANTIBODIES; SUBSTRATE; CLEAVAGE;
D O I
10.1016/j.jtha.2024.02.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Immune-mediated thrombotic thrombocytopenic purpura is caused by autoantibodies against ADAMTS-13, a plasma enzyme that cleaves von Willebrand factor. However, the mechanism resulting in severe de ficiency of plasma ADAMTS-13 activity remains controversial. Objectives: To determine the mechanism of autoantibody-mediated severe de ficiency of plasma ADAMTS13 activity in immune-mediated thrombotic thrombocytopenic purpura. Methods: Fluorescence resonance energy transfer-VWF73 was used to determine plasma ADAMTS-13 activity. Enzyme-linked immunosorbent assay (ELISA) was used to determine anti -ADAMTS-13 immunoglobulin G. ELISA and capillary electrophoresis - based Western blotting were employed to assess plasma ADAMTS-13 antigen. Results: We showed that plasma ADAMTS-13 antigen levels varied substantially in the samples collected on admission despite all showing plasma ADAMTS-13 activity of <10 IU/dL (or <10% of normal level) using either ELISA or Western blotting. More severe de ficiency of plasma ADAMTS-13 antigen ( <10%) was detected in admission samples by ELISA than by capillary Western blotting. There was a signi ficant but moderate correlation between plasma ADAMTS-13 activity and ADAMTS-13 antigen by either assay method, suggesting that severe de ficiency of plasma ADAMTS-13 activity is not entirely associated with low levels of ADAMTS-13 antigen. Conclusion: We conclude that severe de ficiency of plasma ADAMTS-13 activity primarily resulted from antibody-mediated inhibition, but the accelerated clearance of plasma ADAMTS-13 antigen via immune complexes may also contribute signi ficantly to severe de ficiency of plasma ADAMTS-13 activity in a subset of patients with acute immune-mediated thrombotic thrombocytopenic purpura.
引用
收藏
页码:1358 / 1365
页数:8
相关论文
共 50 条
  • [41] Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
    De Waele, Laure
    Sakai, Kazuya
    Mancini, Ilaria
    Sinkovits, Gyoergy
    Falter, Tanja
    Inoue, Takashi
    Agosti, Pasquale
    Rossmann, Heidi
    Von Auer, Charis
    Tersteeg, Claudia
    Meyer, Simon F. De
    Joly, Berangere S.
    Veyradier, Agnes
    Coppo, Paul
    Fijnheer, Rob
    Peyvandi, Flora
    Prohaszka, Zoltan
    Laemmle, Bernhard
    Vanhoorelbeke, Karen
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 493 - 502
  • [42] Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura
    Kobayashi, Toshihiko
    Wada, Hideo
    Kamikura, Yuko
    Matsumoto, Takeshi
    Mori, Yoshitaka
    Kaneko, Toshihiro
    Nobori, Tsutomu
    Matsumoto, Masanori
    Fujimura, Yoshihiro
    Shiku, Hiroshi
    THROMBOSIS RESEARCH, 2007, 119 (04) : 447 - 452
  • [43] Goodpasture’s syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit
    Cristina Vega-Cabrera
    Gloria Del Peso
    Auxiliadora Bajo
    M.-Luz Picazo
    Begoña Rivas-Becerra
    Ana-Lidia Benitez
    Jorge Martínez Ara
    Teresa Olea
    Rafael Selgas
    International Urology and Nephrology, 2013, 45 : 1785 - 1789
  • [44] Recombinant ADAMTS13 in Severe Neonatal Thrombotic Thrombocytopenic Purpura
    Stubbs, Matthew J.
    Kendall, Giles
    Scully, Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (25): : 2391 - 2392
  • [45] Recombinant ADAMTS-13 as a tool to gain insight into the pathophysiology of thrombotic thrombocytopenic purpura (TTP)
    Scheiflinger, F
    Rieger, M
    Plaimauer, B
    PROCEEDINGS OF THE XVII MEETING INTERNATIONAL SOCIETY OF HAEMATOLOGY (EUROPEAN AND AFRICAN DIVISION), 2003, : 83 - 89
  • [46] ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura
    Sui, Jingrui
    Zheng, Liang
    Zheng, X. Long
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (08) : 974 - 979
  • [47] Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura
    Colliou, Eloise
    Ribes, Agnes
    Gaible, Clotilde
    Marlas, Mathilde
    Ribes, David
    Labadens, Isabelle
    Guerby, Paul
    Faguer, Stanislas
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [48] ADAMTS13 and thrombotic thrombocytopenic purpura
    Lämmle, B
    Bianchi, V
    Alberio, L
    Furlan, M
    BLOOD, 2002, 100 (10) : 3840 - 3841
  • [49] Deficiency of ADAMTS 13 in thrombotic thrombocytopenic purpura
    Tsai, HM
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 2) : 132 - 138
  • [50] ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
    Feys, HB
    Liu, F
    Dong, N
    Pareyn, I
    Vauterin, S
    Vandeputte, N
    Noppe, W
    Ruan, C
    Deckmyn, H
    Vanhoorelbeke, K
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (05) : 955 - 962